Last reviewed · How we verify
Efficacy and safety of olmesartan associated with chlorthalidone in essential arterial hypertension — Treatment Landscape & Competitive Intelligence
0 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Efficacy and safety of olmesartan associated with chlorthalidone in essential arterial hypertension:
- Efficacy and safety of olmesartan associated with chlorthalidone in essential arterial hypertension treatment updates — RSS
- Efficacy and safety of olmesartan associated with chlorthalidone in essential arterial hypertension treatment updates — Atom
- Efficacy and safety of olmesartan associated with chlorthalidone in essential arterial hypertension treatment updates — JSON
Cite this brief
Drug Landscape (2026). Efficacy and safety of olmesartan associated with chlorthalidone in essential arterial hypertension — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/efficacy-and-safety-of-olmesartan-associated-with-chlorthalidone-in-essential-arterial-hypertension. Accessed 2026-06-10.
Related
- Efficacy and safety of olmesartan associated with chlorthalidone in essential arterial hypertension full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing